

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 December 2005 (01.12.2005)

PCT

(10) International Publication Number  
**WO 2005/113502 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 209/88**

(21) International Application Number:  
**PCT/GB2005/001978**

(22) International Filing Date: 19 May 2005 (19.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0411273.6 20 May 2004 (20.05.2004) GB

(71) Applicant (for all designated States except US): **CIPLA LIMITED** [IN/IN]; 289 Bellasis Road, Mumbai central, Mumbai 400 008 (IN).

(71) Applicant (for MW only): **WAIN, Christopher, Paul** [GB/GB]; 235 High Holborn, London WC1V 7LE (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KANKAN, Rajendra, Narayanrao** [IN/IN]; A-3/5, NBD Society, NSS

Road, Ghatkopar (West, Mumbai 400 084 (IN). **RAO, Dharmaraj, Ramachandra** [IN/IN]; 4/403 Garden Enclave, Pokharan Road 2, Thane West, Mumbai 400 601, Maharashtra (IN).



(74) Agents: **CURTIS, Philip, Anthony et al.; A.A. Thornton & Co.**, 235 High Holborn, London WC1V 7LE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: **PROCESS FOR THE PREPARATION OF CARVEDILOL**



(57) Abstract: A process for the preparation of carvedilol of formula (I) (I) either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, which process comprises reacting 2,3-epoxypropoxy carbazole of formula (II) (II) or the R or S enantiomer thereof, with N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) (V) to yield benzyl carvedilol of formula (VI) (VI) which is debenzylated by catalytic hydrogenation to yield carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and/or, if desired, separating the enantiomers. The above process is characterised in that reaction of said 2,3-epoxypropoxy carbazole of formula (II) with said N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) is carried out in water as the reaction medium. The present invention further provides carvedilol of formula (I) prepared by a process as described above, and pharmaceutical compositions containing the same and therapeutic uses thereof.



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*

## PROCESS FOR THE PREPARATION OF CARVEDILOL


The present invention is concerned with a new process for preparing 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol of formula (I)



(I)


The above compound of formula (I) is known under the INN name of carvedilol and is used as a drug having antihypertensive, beta-adrenergic blocking and vasodilating activity.

The preparation of carvedilol has been known from DE 2815926, while the preparation of the R and S enantiomers has been described in DE 3313027. More particularly, 2,3-epoxypropoxy carbazole of formula (II)




(II)

or the R or S enantiomer thereof, is reacted with 2-[2'-(methoxy)-phenoxy]-ethylamine of formula (III)




to produce carvedilol in a yield of 39 to 42%. A drawback of this known process is that in addition to the formation of carvedilol, the following bis compound of formula (IV) is also formed




Further processes for the preparation of carvedilol have also been described in DE 2815926. In Example 5 of DE 2815926, 2,3-epoxypropoxy carbazole of above formula (II) is reacted with the secondary amine N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V)

3



(V)

to yield benzyl carvedilol of formula (VI)




(VI)

The thus formed benzyl carvedilol of formula (VI) required column chromatography for separation.


EP 0918055 describes a process for the preparation of carvedilol, which is characterised in that 2,3-epoxypropoxy carbazole of formula (II) is reacted with N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) in the presence of a protic organic solvent and the thus formed benzyl carvedilol of formula (VI) is debenzylated by catalytic hydrogenation.

The present invention now provides an improved process for the preparation of carvedilol of formula (I)




either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof,


which process comprises reacting 2,3-epoxypropoxy carbazole of formula (II)



or the R or S enantiomer thereof, with N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V)



to yield the benzyl carvedilol of formula (VI)




(VI)

which is debenzylated by catalytic hydrogenation to yield carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers;

which process is characterised in that reaction of said 2,3-epoxypropoxy carbazole of formula (II) with said N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) is carried out in water as the reaction medium.


Preferably in a process according to the present invention 2,3-epoxypropoxy carbazole of formula (II) is prepared from 4-hydroxy carbazole of formula (VII)



(VII)

which process step can also be characterised as being carried out in water as the reaction medium.

It is further preferred that in a process according to the present invention 4-hydroxy carbazole of formula (VII) is prepared from 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII)




which process step can also be characterised as being carried out in water as the reaction medium.

A process according to the present invention of preparing carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, can thus be represented by the following reaction scheme



7



and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers,


characterised in that at least for reaction of compounds of formulae (II) and (V), this process step is carried out in water as the reaction medium. More preferably, for a process as

represented by the above reaction scheme each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in water as the reaction medium.

A process according to the present invention is advantageous in that it allows the preparation of carvedilol of formula (I) from 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII) by intermediate process steps which up to and including the preparation of benzyl carvedilol of formula (VI) can each be carried out in water as the reaction medium. 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII) is a known compound and can be prepared under aqueous conditions from 1,3-cyclohexanedione and phenyl hydrazine, typically as described in Example 1 of US patent application no. 4273711. Intermediates (VII), (II) and (VI) can be isolated at each intermediate process stage; alternatively a process as represented by the above scheme can be carried out as a one-pot process. A process according to the present invention can thus offer the advantages of being environmentally friendly (with no organic solvent being used for the reaction), can achieve an improved yield compared to prior art processes and is industrially applicable for large scale production.

There is further provided by the present invention, therefore, a process of preparing carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, which can be represented by the following reaction scheme

9



and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers,

characterised in that the process steps leading to the preparation of benzyl carvedilol of formula (VI) are carried out as a one-pot process in water as the reaction medium.

Debenzylation of benzyl carvedilol of formula (VI) by catalytic hydrogenation can be carried out in a manner known per se in connection with the removal of a benzyl group. Preferably as a catalyst palladium on carbon is used. Suitably, hydrogen gas is bubbled through the reaction mixture at room temperature and the temperature is then raised to 45 - 50°C and the bubbling of hydrogen gas is continued for a further 8 hours. Typically, the reaction mass is filtered to remove the catalyst and the filtrate is subsequently concentrated to remove solvent. The resulting contents can then be chilled, filtered and washed to provide carvedilol of formula (I).

Reaction of compounds of formulae (II) and (V) to yield benzyl carvedilol of formula (VI) is carried out in water as the reaction medium substantially as hereinbefore described and preferably also in the presence of a base, such as an alkali metal carbonate, typically potassium carbonate or the like. The reaction mixture is suitably heated and stirred for several hours and the resulting contents can then be cooled, filtered and washed to provide benzyl carvedilol of formula (VI).

N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) can be prepared by techniques known in the art, for example as described in J. Med. Chem., 8 [1965], 356 to 367.

2,3-Epoxypropoxy carbazole of formula (II) can be prepared from 4-hydroxy carbazole of formula (VII) by reaction of the latter with epichlorohydrin in water as the reaction medium substantially as hereinbefore described and preferably also in the presence of a phase transfer catalyst, such as tetrabutyl ammonium bromide or the like. Suitably a base is present in the reaction mixture, such as an alkali metal hydroxide, typically sodium hydroxide or the like.

4-Hydroxy carbazole of formula (VII) is in turn prepared from 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII) in a process according to the present invention, typically by employing a catalyst known to be suitable for the hydration of double bonds, such as Raney nickel, in water as the reaction medium and again suitably in the presence of a base, such as an alkali metal hydroxide, typically sodium hydroxide or the like.

In a preferred embodiment, the reaction of compound II with compound V is carried out in the absence of an organic acid.

In a preferred embodiment, the reaction of compound II with compound V is carried out in the absence of an aprotic solvent.

In a preferred embodiment, the reaction of compound II with compound V is carried out in the absence of ethers, esters, ketones, amides, nitriles, hydrocarbons, hydrobromides, halogenated hydrocarbons, and aromatic solvents.

In a preferred embodiment, the reaction of compound II with compound V is carried out in the absence of dioxane, tetrahydrofuran, dimethoxyethane, diisopropylether, methyltertbutylether, ethyl acetate and methylacetate.

In a preferred embodiment, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in the absence of an organic acid.

In a preferred embodiment, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in the absence of an aprotic solvent.

In a preferred embodiment, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in the absence of ethers, esters, ketones, amides, nitriles, hydrocarbons, hydrobromides, halogenated hydrocarbons, and aromatic solvents.

In a preferred embodiment, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in the absence of dioxane, tetrahydrofuran, dimethoxyethane, diisopropylether, methyltertbutylether, ethyl acetate and methylacetate.

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\geq 1$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\geq 10$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\geq 20$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\geq 40$ .

Typically, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\leq 100$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the weight ratio of compound II to water is 1 to  $\geq 0.5$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the weight ratio of compound II to water is 1 to  $\geq 1.0$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the weight ratio of compound II to water is 1 to  $\geq 2.0$ .

In a preferred embodiment, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the weight ratio of compound II to water is 1 to  $\geq 4.0$ .

Typically, the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\leq 10$ .

There is further provided by the present invention carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, prepared by a process substantially as hereinbefore described.

There is further provided by the present invention carvedilol of formula (I) as prepared by a process according to the present invention, for use in therapy.

Carvedilol of formula (I) as provided by a process according to the present invention is known to have vasodilatory and beta-adrenergic blocking action. Carvedilol of formula (I)

as provided by the present invention is, therefore, suitable for the treatment and prophylaxis of circulatory and cardiac diseases, for example hypertension and angina pectoris.

The present invention further provide, therefore, a pharmaceutical composition for the treatment and prophylaxis of hypertension and / or angina pectoris, which composition comprises a pharmaceutically acceptable carrier and in a therapeutically effective amount carvedilol of formula (I) as provided by the present invention.

For the preparation of a pharmaceutical composition according to the present invention, carvedilol of formula (I) as provided by the present invention can be mixed in the usual manner with appropriate pharmaceutical carrier materials, aroma, flavoring and coloring materials as required and, for example, formulated into tablets, or with the addition of appropriate adjuvants, suspended or dissolved in water or in an oil.

Carvedilol of formula (I) as provided by the present invention can be administered enterally or parenterally in liquid or solid form. As injection medium, it is preferable to use water which contains the additives usual in the case of injection solutions, such as stabilizing agents, solubilizing agents and / or buffers. Additives of this type include, for example, tartrate and citrate buffers, ethanol, complex-forming agents (such as ethylenediaminetetraacetic acid and the non-toxic salts thereof) and high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation. Solid carrier materials are, for example starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as stearic acid), gelatine, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats and solid high molecular weight polymers (such as polyethylene glycols). Compositions suitable for oral administration can, if desired, contain flavoring and / or sweetening materials.

There is further provided by the present invention carvedilol of formula (I) as provided by the present invention, for use in the manufacture of a medicament for the treatment of hypertension and / or angina pectoris.

There is still further provided by the present invention a method of treating a subject suffering from or susceptible to hypertension and / or angina pectoris, which method comprises administering to such subject a therapeutically effective amount of carvedilol of formula (I) as provided by the present invention.

In actual administration of carvedilol of formula (I) as provided by the present invention, e.g., in the treatment of hypertension or angina pectoris, the appropriate dosage is of course dependent on the condition of the patient and the specific infirmity to be treated. In general, treatment should begin with small doses (e.g. 100 mg) and be increased gradually depending upon the patient's response. The dosage can be increased at 5 to 7 day intervals until an average daily dosage of 100 to 300 mg is reached. For maintenance, 2 to 4 doses a day are usually required. These dosage levels will generally be appropriate, both for achieving a vasodilating effect, i.e., for reducing blood pressure, and for inhibition of adrenergic beta-receptor activity.

The present invention will now be further illustrated by the following Example, which does not limit the scope of the invention in anyway.

#### Example

##### Step 1: Preparation of 4-hydroxy carbazole

To a reactor containing water (1L) was added Raney nickel (35g) followed by 1,2,3,9-tetrahydrocarbazole-4-one (50g) and sodium hydroxide (15g). The contents were heated to reflux and maintained for about 20 hours. The catalyst was filtered off and the filtrate was acidified to obtain a solid, which was filtered and dried to obtain the title compound. When necessary, the title compound was further purified by dissolving in 10% sodium hydroxide solution, treating with activated charcoal and precipitation from dilute hydrochloric acid to give off-white to grey crystals of 4-hydroxy carbazole in 50% yield.

##### Step 2: Preparation of 2,3-Epoxypropoxy carbazole

4-Hydroxy carbazole (60g) obtained in step 1 was charged into a reactor containing water (90ml). Epichlorohydrin (64.2g) and tetrabutyl ammonium bromide (6.3g) were then charged into the reactor under stirring. 50% Sodium hydroxide solution (78g) was added slowly in 2 – 3 hours into the reaction mass at about 30°C. After completion of reaction, ethyl acetate (315ml) and potable water (315ml) were charged into the reaction mass. The



lower aqueous layer was separated and discarded. The ethyl acetate layer was washed with potable water to obtain neutral pH and dried over anhydrous sodium sulphate. The ethyl acetate is distilled out under vacuum below 55°C to about 100ml. The reaction mass was chilled to 0 – 5°C and filtered and dried at 50-60°C to give the title compound (50g) (64%).

Step 3: Preparation of N-Benzyl carvedilol


Epoxy carbazole (100g) obtained in step 2 was charged to water (500ml) under stirring followed by potassium carbonate (112g) and N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine (140g) at room temperature. The contents were heated to 80 – 90°C and stirred for 3 hours at 85 – 90°C. The reaction mass was cooled to 30 – 35°C and water was decanted. Fresh water (1L) was added and the mass stirred to obtain a solid which was filtered and washed with water to obtain the title compound (205g) (99%).

Step 4: Preparation of Carvedilol

Benzyl carvedilol (205g) obtained in step 3 was charged to ethyl acetate (2400ml) and water (240ml). The contents were stirred and 10% palladium on carbon (20g) was added at room temperature. Hydrogen gas was bubbled at room temperature. The temperature was raised to 45 – 50°C and bubbling was continued for 8 hours. The reaction mass was filtered to remove the catalyst and the filtrate was concentrated to remove solvent (about 2L). The contents were chilled to 15 – 20°C, filtered and washed with chilled ethyl acetate (50ml) to give carvedilol (140g) (84%).

CLAIMS


1. A process for the preparation of carvedilol of formula (I)



(I)

either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof,


which process comprises reacting 2,3-epoxypropoxy carbazole of formula (II)



(II)


or the R or S enantiomer thereof, with N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V)

17



(V)

to yield benzyl carvedilol of formula (VI)




(VI)

which is debenzylated by catalytic hydrogenation to yield carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers;

which process is characterised in that reaction of said 2,3-epoxypropoxy carbazole of formula (II) with said N-[2-(2-methoxy-phenoxy)ethyl]-benzylamine of formula (V) is carried out in water as the reaction medium.


2. A process according to claim 1, wherein 2,3-epoxypropoxy carbazole of formula (II) is prepared from 4-hydroxy carbazole of formula (VII)

18



which process step is characterised as being carried out in water as the reaction medium.


3. A process according to claim 2, wherein said 4-hydroxy carbazole of formula (VII) is prepared from 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII)



which process step is characterised as being carried out in water as the reaction medium.

4. A process of preparing carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, represented by the following reaction scheme

19




and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers,

which process is characterised in that at least for reaction of compounds of formulae (II) and (V), this process step is carried out in water as the reaction medium.

5. A process according to claim 4, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in water as the reaction medium.

6. A process of preparing carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, which process is represented by the following reaction scheme

21



and if desired reacting the thus formed carvedilol of formula (I) with an inorganic or organic acid to yield a pharmaceutically acceptable salt thereof, and / or, if desired, separating the enantiomers,

characterised in that the process steps leading to the preparation of benzyl carvedilol of formula (VI) are carried out as a one-pot process in water as the reaction medium.

7. A process according to any of claims 1 to 6, wherein debenzylation of benzyl carvedilol of formula (VI) is carried out in the presence of palladium on carbon as a catalyst.
8. A process according to any of claims 1 to 7, wherein reaction of compounds of formulae (II) and (V) to yield benzyl carvedilol of formula (VI) is carried out in the presence of a base.
9. A process according to claim 8, wherein said base is potassium carbonate.
10. A process according to any of claims 2 to 9, wherein 2,3-epoxypropoxy carbazole of formula (II) is prepared from 4-hydroxy carbazole of formula (VII) by reaction of the latter with epichlorohydrin in water as the reaction medium.
11. A process according to claim 10, wherein 4-hydroxy carbazole of formula (VII) is reacted with epichlorohydrin in the presence of a phase transfer catalyst.
12. A process according to claim 11, wherein said phase transfer catalyst is tetrabutyl ammonium bromide.
13. A process according to any of claims 10 to 12, which is carried out in the presence of a base.
14. A process according to claim 13, wherein said base is sodium hydroxide.
15. A process according to any of claims 3 to 14, wherein 4-hydroxy carbazole of formula (VII) is prepared from 1,2,3,9-tetrahydrocarbazole-4-one of formula (VIII) using Raney nickel as catalyst.
16. A process according to claim 15, which is carried out in the presence of a base.



17. A process according to claim 16, wherein said base is sodium hydroxide.
18. A process according to any preceding claim, wherein the reaction of compound II with compound V is carried out in the absence of an organic acid
19. A process according to any one of claims 1 to 17, wherein the reaction of compound II with compound V is carried out in the absence of an aprotic solvent.
20. A process according to any one of claims 1 to 17, wherein the reaction of compound II with compound V is carried out in the absence of ethers, esters, ketones, amides, nitriles, hydrocarbons, hydrobromides, halogenated hydrocarbons, and aromatic solvents.
21. A process according to any one of claims 1 to 17, wherein the reaction of compound II with compound V is carried out in the absence of dioxane, tetrahydrofuran, dimethoxyethane, diisopropylether, methyltertbutylether, ethyl acetate and methylacetate.
22. A process according to any one of claims 4 to 6, wherein each of the illustrated intermediate process steps leading to benzyl carvedilol of formula (VI) is carried out in the absence of an aprotic solvent.
23. A process according to any preceding claim, wherein the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the molar ratio of compound II to water is 1 to  $\geq 1$ .
24. A process according to any one of claims 1 to 22, wherein the reaction of compound II with compound V is carried out in the presence of water as the reaction medium in an amount such that the weight ratio of compound II to water is 1 to  $\geq 1$ .

25. Carvedilol of formula (I), either in enantiomeric substantially pure form, or as an enantiomeric mixture, optionally as a pharmaceutically acceptable salt thereof, prepared by a process according to any of claims 1 to 24.

26. Carvedilol of formula (I) according to claim 25, for use in therapy.

27. A pharmaceutical composition for the treatment and prophylaxis of hypertension and / or angina pectoris, which composition comprises a pharmaceutically acceptable carrier and in a therapeutically effective amount carvedilol of formula (I) according to claim 25.

28. Carvedilol of formula (I) according to claim 25, for use in the manufacture of a medicament for the treatment of hypertension and / or angina pectoris.

29. A method of treating a subject suffering from or susceptible to hypertension and / or angina pectoris, which method comprises administering to such subject a therapeutically effective amount of carvedilol of formula (I) according to claim 25,

## INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/EP2005/001978

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D209/88

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X  A	EP 0 918 055 A (EGIS GYOGYSZERGYAR RT) 26 May 1999 (1999-05-26) cited in the application the whole document	25-29  1,4,6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

8 August 2005

Date of mailing of the international search report

22/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

# INTERNATIONAL SEARCH REPORT

In international application No.  
r CT/GB2005/001978

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 29 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2005/001978

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0918055	A	26-05-1999	HU 9802180 A1 28-12-2000
			CZ 9803561 A3 16-06-1999
			DE 69813729 D1 28-05-2003
			DE 69813729 T2 05-02-2004
			DE 69823394 D1 27-05-2004
			DE 69823394 T2 04-05-2005
			EP 1142873 A2 10-10-2001
			EP 1142874 A2 10-10-2001
			EP 0918055 A1 26-05-1999
			ES 2221875 T3 16-01-2005
			ES 2196459 T3 16-12-2003
			HR 980590 A1 31-10-1999
			PL 329828 A1 07-06-1999
			RU 2216539 C2 20-11-2003
			SI 918055 T1 31-12-2003
			SI 1142873 T1 31-12-2004
			SK 156098 A3 11-06-1999